HomeUSABeyond Celiac Launches First Investment Program for Celiac Disease Therapeutics

Beyond Celiac Launches First Investment Program for Celiac Disease Therapeutics

beyond celiac

Beyond Celiac, a Philadelphia, PA-based catalyst for a cure for celiac disease, created an investment program to accelerate the development of treatments and a cure for celiac disease by leveraging the speed and scale of venture capital and capital markets.

Beyond Celiac Investments (BCI) launches with an initial funding of $2m and additional capital will be raised through donations.

BCI is using the Development Catalyst business model, designed to increase development and commercialization activity across the Celiac treatment spectrum. The model enables drug development through nonprofit means. Using donated funds also means that all financial returns from BCI’s investments return to Beyond Celiac to be used for future investments and grants to benefit Beyond Celiac’s cure acceleration mission and celiac disease population.

The Beyond Celiac Investment Team includes Alice Bast, President and CEO; Jordan Dubow, M.D., Chief Medical Officer; Debra Silberg, M.D., Ph.D., Chief Scientific Officer; and Eric White, Fund Manager.

Inquiries about investing should be directed to investments@beyondceliac.org.

Founded in 2003, Beyond Celiac is a catalyst for a celiac disease cure in the United States, serving as a patient advocacy and research-driven organization working to drive diagnosis and accelerate the discovery of new treatments.